Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949538 | 1.00 | STS (0.44) | STSTGFBR1GPR119JAK2JAK1 | |
| SCHEMBL3949543 | 1.00 | STS (0.44) | STSTGFBR1GPR119JAK2JAK1 | |
| SCHEMBL7954191 | 0.87 | TGFBR1 (0.48) | STSTGFBR1GPR119JAK2JAK1 | |
| SCHEMBL505550 | 0.85 | GPR119 (0.48) | STSGPR119EPHX2 | |
| SCHEMBL856352 | 0.85 | GPR119 (0.48) | STSGPR119EPHX2 | |
| SCHEMBL856350 | 0.85 | GPR119 (0.48) | STSGPR119EPHX2 | |
| SCHEMBL856351 | 0.85 | GPR119 (0.48) | STSGPR119EPHX2 | |
| SCHEMBL857313 | 0.85 | GPR119 (0.48) | STSGPR119EPHX2 | |
| SCHEMBL29895401 | 0.85 | GPR119 (0.48) | STSGPR119EPHX2 | |
| SCHEMBL1879006 | 0.85 | TGFBR1 (0.52) | STSTGFBR1GPR119KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498347-B2 | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4 antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| US-20060142340-A1 | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142340-A1 | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4 antagonists | HTR4, HTR2B, HTR3B | STS 3382/4885TGFBR1 2347/4885GPR119 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.